júlí 2005
júlí 2005
júlí 2005
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
7/05<br />
(74) Faktor einkaleyfaskrifstofa, ehf.,<br />
Pósthólf 678, 121 Reykjavík.<br />
(62) 6472<br />
(30) 23.2.2000, GB, 00 04297.8<br />
(85) 29.6.<strong>2005</strong><br />
(86) 21.2.2001, PCT/EP01/01956<br />
(21) 7920<br />
(22) 29.6.<strong>2005</strong><br />
(24) 21.2.2001<br />
(41) 29.6.<strong>2005</strong><br />
(51) C07D 207/27<br />
(54) 2-oxó-1-pýrrólidín afleiður, aðferð til<br />
framleiðslu á þeim og notkun þeirra.<br />
(71) UCB Farchim, S.A. (AG - LTD), Z.I.<br />
Planchy, Chemin de Croix Blanche,<br />
10, C.P. 411, CH-1630 Bulle, Sviss.<br />
(72) John Surtees, Jezus-Eik Overijse,<br />
Belgíu; Violeta Marmon, Abingdon,<br />
Oxfordshire, Bretlandi; Edmond<br />
Differding, Ottignies-Louvain-la-<br />
Neuve, Belgíu; Vincent<br />
Zimmermann, Bruxelles, Belgíu.<br />
(74) Faktor einkaleyfaskrifstofa, ehf.,<br />
Pósthólf 678, 121 Reykjavík.<br />
(62) 6472<br />
(30) 23.2.2000, GB, 00 04297.8<br />
(85) 29.6.<strong>2005</strong><br />
(86) 21.2.2001, PCT/EP01/01956<br />
(21) 7921<br />
(22) 29.6.<strong>2005</strong><br />
(24) 21.2.2001<br />
(41) 29.6.<strong>2005</strong><br />
(51) C07D 207/00<br />
(54) 2-oxó-1-pýrrólidín afleiða og<br />
lyfjafræðileg notkun hennar.<br />
(71) UCB, S.A., Allée de la Recherche<br />
60, B-1070 Brussels, Belgíu.<br />
(72) Edmond Differding, Ottignies-<br />
Louvain-la-Neuve; Bénedicte<br />
Lallemand, Waimes; Benoît Kenda,<br />
Emines; Alain Matagne, Gerpinnes;<br />
Philippe Michel, Beersel; Patrick<br />
Pasau, Chastre; Patrice Talaga,<br />
Watermael-Boitsfort; Belgíu.<br />
(74) Faktor einkaleyfaskrifstofa, ehf.,<br />
Pósthólf 678, 121 Reykjavík.<br />
(62) 6481<br />
(30) 23.2.2000, GB, 00 04297.8<br />
(85) 29.6.<strong>2005</strong><br />
(86) 21.2.2001, PCT/EP01/01992<br />
(21) 7922<br />
(22) 29.6.<strong>2005</strong><br />
(24) 21.2.2001<br />
(41) 29.6.<strong>2005</strong><br />
(51) C07D 207/00<br />
(54) 2-oxó-1-pýrrólidín afleiða og<br />
lyfjafræðileg notkun hennar.<br />
(71) UCB, S.A., Allée de la Recherche<br />
60, B-1070 Brussels, Belgíu.<br />
(72) Edmond Differding, Ottignies-<br />
Louvain-la-Neuve; Bénedicte<br />
Lallemand, Waimes; Benoît Kenda,<br />
Emines; Alain Matagne, Gerpinnes;<br />
Philippe Michel, Beersel; Patrick<br />
Pasau, Chastre; Patrice Talaga,<br />
Watermael-Boitsfort; Belgíu.<br />
(74) Faktor einkaleyfaskrifstofa, ehf.,<br />
Pósthólf 678, 121 Reykjavík.<br />
(62) 6481<br />
(30) 23.2.2000, GB, 00 04297.8<br />
ELS tíðindi 65<br />
(85) 29.6.<strong>2005</strong><br />
(86) 21.2.2001, PCT/EP01/01992<br />
(21) 7923<br />
(22) 29.6.<strong>2005</strong><br />
(24) 21.2.2001<br />
(41) 29.6.<strong>2005</strong><br />
(51) C07D 207/00<br />
(54) 2-oxó-1-pýrrólidín afleiða og<br />
lyfjafræðileg notkun hennar.<br />
(71) UCB, S.A., Allée de la Recherche<br />
60, B-1070 Brussels, Belgíu.<br />
(72) Edmond Differding, Ottignies-<br />
Louvain-la-Neuve; Bénedicte<br />
Lallemand, Waimes; Benoît Kenda,<br />
Emines; Alain Matagne, Gerpinnes;<br />
Philippe Michel, Beersel; Patrick<br />
Pasau, Chastre; Patrice Talaga,<br />
Watermael-Boitsfort; Belgíu.<br />
(74) Faktor einkaleyfaskrifstofa, ehf.,<br />
Pósthólf 678, 121 Reykjavík.<br />
(62) 6481<br />
(30) 23.2.2000, GB, 00 04297.8<br />
(85) 29.6.<strong>2005</strong><br />
(86) 21.2.2001, PCT/EP01/01992<br />
(21) 7924<br />
(22) 30.6.<strong>2005</strong><br />
(41) 30.6.<strong>2005</strong><br />
(51) C07C 271/28; C07C 233/43; A61P<br />
25/08; A61K 31/167; A61K 31/325<br />
(54) Setnar anilín afleiður.<br />
(71) H. Lundbeck A/S, 9, Ottiliavej, DK-<br />
2500 Valby-Copenhagen, Danmörku.<br />
(72) Daniel Rodriguez Greve, Stenløse;<br />
Mario Rottländer, Greve; William<br />
Patrick Watson, Vanløse; Danmörku.<br />
(74) Faktor einkaleyfaskrifstofa, ehf.,<br />
Pósthólf 678, 121 Reykjavík.<br />
(30) 14.3.2003, DK, PA200300392<br />
(85) 30.6.<strong>2005</strong><br />
(86) 12.3.2004, PCT/DK2004/000162<br />
(21) 7925<br />
(22) 30.6.<strong>2005</strong><br />
(41) 30.6.<strong>2005</strong><br />
(51) C07D 207/26; C07D 279/02; C07D<br />
417/12; C07D 405/12; C07D 409/12;<br />
C07D 403/12; C07D 401/12; C07D<br />
275/02; C07D 211/76; A61K 31/<br />
4015; A61K 31/45; A61K 31/415;<br />
A61K 31/541; A61P 25/28<br />
(54) Hýdroxýetýlamínafleiður til að<br />
meðhöndla Alzheimers-sjúkdóm.<br />
(71) Glaxo Group Limited, Glaxo<br />
Wellcome House, Berkeley Avenue,<br />
Greenford, Middlesex UB6 0NN,<br />
Bretlandi.<br />
(72) Emmanuel H. Demont, Harlow,<br />
Essex; Andrew Faller, Windlesham,<br />
Surrey; David Timothy Macpherson,<br />
Harlow, Essex; Peter Henry Milner,<br />
Harlow, Essex; Alan Naylor, Harlow,<br />
Essex; Sally Redshaw, Harlow,<br />
Essex; Steven James Stanway,<br />
Harlow, Essex; David R. Vesey,<br />
Harlow, Essex; Daryl S. Walter,<br />
Harlow, Essex; Bretlandi.<br />
(74) Sigurjónsson & Thor, ehf.,<br />
Skólavörðustíg 16, 101 Reykjavík.<br />
(30) 5.12.2002, GB, 0228410.7<br />
(85) 30.6.<strong>2005</strong><br />
(86) 3.12.2003, PCT/EP2003/013806<br />
Endurauglýstar<br />
umsóknir<br />
Eftirtaldar einkaleyfisumsóknir<br />
eru öllum<br />
aðgengilegar hjá Einkaleyfastofu,<br />
í samræmi við<br />
2. og 4. mgr. 22. gr. laga nr.<br />
17/1991 um einkaleyfi, með<br />
síðari breytingum, að<br />
liðnum 18 mánaða<br />
leyndartíma talið frá<br />
umsóknar- eða<br />
forgangsréttardegi.<br />
(21) 7846<br />
(22) 13.5.<strong>2005</strong><br />
(41) 13.5.<strong>2005</strong><br />
(51) C07C 281/18<br />
(54) Aðferð til að framleiða lyfjafræðilega<br />
virkt efnasamband og til að framleiða<br />
milliefni þess.<br />
(71) Vita Científica, S.L., Avenida<br />
Barcelona, 69, 08970 Sant Joan<br />
Despi, Spáni.<br />
(72) Pere Dalmases Barjoan; Jordi Bessa<br />
Bellmunt; Barcelona, Spáni.<br />
(74) Sigurjónsson & Thor, ehf.,<br />
Skólavörðustíg 16, 101 Reykjavík.<br />
(30) 31.10.2002, ES, P-200202502<br />
(85) 13.5.<strong>2005</strong><br />
(86) 27.10.2003, PCT/IB2003/004763<br />
(21) 7848<br />
(22) 17.5.<strong>2005</strong><br />
(41) 17.5.<strong>2005</strong><br />
(51) C07D 307/87; A61K 31/343; A61P<br />
25/00; A61P 25/22; A61P 25/24;<br />
A61P 25/30<br />
(54) Essítalópram hýdróbrómíð og aðferð<br />
til framleiðslu þess.<br />
(71) H. Lundbeck A/S, 9, Ottiliavej, DK-<br />
2500 Valby-Copenhagen, Danmörku.<br />
(72) Lawrence Martel, Manchester,<br />
Bandaríkjunum; Robert Dancer,<br />
Hvidovre, Danmörku; Hans<br />
Petersen, Vanløse, Danmörku; Peter<br />
Ellegaard, Jystrup, Danmörku.<br />
(74) Faktor einkaleyfaskrifstofa, ehf.,<br />
Pósthólf 678, 121 Reykjavík.<br />
(30) 23.12.2002, DK, PA 2002 0<strong>2005</strong><br />
(85) 17.5.<strong>2005</strong><br />
(86) 18.12.2003, PCT/DK03/000902<br />
(21) 7849<br />
(22) 19.5.<strong>2005</strong><br />
(41) 19.5.<strong>2005</strong><br />
(51) C07D 491/04; C07D 519/00; A61K<br />
31/517; A61P 35/00<br />
(54) Kínasólínafleiður sem SRC<br />
týrósínkínasatálmar.<br />
(71) Astra Zeneca AB, SE-151 85<br />
Södertälje, Svíþjóð.<br />
(72) Patrick Ple, Reims Cedex,<br />
Frakklandi.<br />
(74) Sigurjónsson & Thor, ehf.,<br />
Skólavörðustíg 16, 101 Reykjavík.